Trillium Therapeutics Inc.
CD47 BLOCKADE WITH PARP INHIBITION FOR DISEASE TREATMENT

Abstract:

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRP.alpha.Fc and the PARP inhibitor niraparib. The anti-cancer effect of niraparib is enhanced in the presence of SIRP.alpha.Fc. Specific combinations include SIRP.alpha.Fc forms that comprise an Fc that is either IgG1 or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.